Biologics News
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
August 7, 2025
Cary, N.C. , August 7, 2025 – Effective June 15, VIJOICE® (alpelisib) is now exclusively available at Biologics by McKesson,
ENSACOVE™ (ensartinib), FDA-Approved Treatment for Adult Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer, Exclusively Available at Biologics by McKesson
July 14, 2025
Cary, N.C. , July 14, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
July 1, 2025
Cary, N.C., July 1, 2025 – Effective July 1st, Bristol Myers Squibb Co. has reduced its specialty pharmacy network for
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
June 11, 2025
Cary, N.C. , June 11, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
May 20, 2025
Cary, N.C. , May 20, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) FDA Approved for the Treatment of Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer who have Received Prior Systemic Therapy, Available at Biologics by McKesson
May 9, 2025
Cary, N.C. , May 9, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease